ClinicalTrials.Veeva

Menu

Treatment With Rhinospray Plus in Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary

Boehringer Ingelheim logo

Boehringer Ingelheim

Status

Completed

Conditions

Rhinitis

Study type

Observational

Funder types

Industry

Identifiers

Details and patient eligibility

About

Multi-centre, open-label, prospective, uncontrolled, single-arm, non-interventional study (NIS) with objective to collect and evaluate data concerning treatment with Rhinospray Plus in everyday curative routine treatment of acute rhinitis

Full description

Study Design:

open, observational, single-arm, uncontrolled

Enrollment

300 patients

Sex

All

Ages

6+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients who (or in case of 6-18 years old whose legal representative) have signed the Informed Consent
  2. Male and female ambulatory outpatients being seen in a participating physicians office for routine care
  3. Patients with a clinical diagnosis of Rhinitis acuta
  4. Patient having the cognitive and functional abilities for answering the symptom specific questions
  5. Patients having expressed the willingness to participate in this observational study
  6. Patients at and above the age of 6
  7. Rhinospray Plus naive patients (patients who have not used Rhinospray Plus before)

Exclusion criteria

  1. Uncooperative patients based on physicians judgement
  2. Patients with any conditions making the application of Rhinospray plus contraindicated
  3. Patients currently enrolled in any clinical trial which requires a change in medication for their respiratory problems
  4. Withdraw of Informed Consent
  5. Pregnancy or breast-feeding as stated in the Summary of Product Characteristic (SmPC)
  6. Patients with clinical diagnosis of allergic rhinitis

Trial design

300 participants in 1 patient group

acute rhinitis

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems